Nyrada

Cardioprotection Program

23-Oct-2024	Supplementary NYR-BI03 Study Confirm Strong Cardioprotection

16-Oct-2024	NYR Completes Safety Studies Ahead of Phase I Clinical Trial

1-Oct-2024	Drug Candidate Demonstrates Significant Cardioprotection

26-Jun-2023	Cholesterol-Lowering Program Update

26-May-2023	Cholesterol-Lowering Program Preclinical Studies Completed

11-Apr-2023	Cholesterol-Lowering Program Preclinical Development Update

10-Oct-2022	Efficacy Study Published in Journal of Lipid Research

20-Jul-2022	Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis

29-Jun-2022	Cholesterol-Lowering Program Update

17-May-2022	European Patent to be Granted for Cholesterol-Lowering Drug

22-Dec-2021	Cholesterol-Lowering Program Pathway to Phase I

13-Aug-2021	NYX-PCSK9i In Vivo Study Exploratory Analysis Results

30-Jul-2021	Nyrada Announces US Patent Grant for PCSK9 Inhibitor

29-Jun-2021	NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction

5-May-2021	NYR Announces New Potent Cholesterol-Lowering Candidates

25-Jan-2021	Nyrada Reports Further Results from Cholesterol Study

21-Dec-2020	57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study

6-Jul-2020	Nyrada Cholesterol-Lowering Drug Study Results

11-Feb-2020	Significant advance in Nyrada PCSK9i program published

Copyright © Nyrada